1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Market Study on Uveitis Treatment: Asia to Witness fastest Growth by 2020

Uveitis, also known as intraocular inflammation, refers to swelling of the middle layer of the eye, commonly known as uvea. Uveitis is common across all age groups, although it is more prevalent in the age group of 20 years - 50 years. Autoimmune disorders, injuries, inflammatory disorders, and surgeries are some common causes of uveitis. Anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis are the common types of uveitis; among these, anterior uveitis is the most common type of uveitis. Uveitis may be acute, chronic, or recurrent. Common symptoms associated with uveitis include blurred vision, eye pain, eye floaters, redness of the eye, and increased sensitivity to light. Treatment for uveitis varies according to the type of uveitis and primarily helps reduce the pain, subdue inflammation, control tissue damage, and restore vision. Anti-inflammatory medication, antibiotics, and immunosuppressive medications are common treatments available for the disease. Corticosteroid and topical cyclosporine medications are most commonly used to treat uveitis.

North America dominates the global market for uveitis treatment. This is primarily due to rising incidence of uveitis and related disorders, increasing aging population, and growing R&D investments by drug manufacturing companies in the region. Moreover, rising awareness about uveitis is also boosting the growth of the market. The market in Asia is expected to exhibit rapid growth over the next five years. Japan and China are expected to be the fastest growing uveitis treatment markets in the Asian region. Furthermore, the uveitis treatment market in India is also growing due to rising number of uveitis cases and increasing aging population. Some of the key driving forces for uveitis treatment market in emerging countries are the rise in disposable income and a large pool of patients.

In recent times, treatment options for uveitis have increased such as corticosteroids and anti-inflammatory drugs due to rising in number of uveitis cases. The increasing prevalence of eye disorders and rising R&D investments in drug discovery and development are also fueling the growth of the global uveitis treatment market. On the other hand, lack of awareness about eye disorders and poor primary healthcare infrastructure coupled with a lack of health insurance in developing countries are restraining the growth of the uveitis treatment market. Increasing usage of anti-TNF-alpha inhibitor therapy is a recent trend in the global uveitis treatment market. Strong product pipeline and development of molecules from the newer class of uveitis treatment are expected to create opportunities for the growth of the global uveitis treatment market.

This report provides in-depth analysis and estimation of the uveitis treatment market for the period 2014–2020, considering 2013 as the base year for the calculation. Moreover, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report. The uveitis treatment market is categorized on the basis of type, treatment, and geography. Based on the type of uveitis, the market comprises anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. Based on treatment, uveitis treatment includes anti-inflammatory medication, antibiotic/antiviral medication, and immunosuppressive medications. On the basis of geography, the report identifies and analyzes the market size and predictions for North America, Europe, Asia, and Rest of the World (RoW).

Some of the major players in the uveitis treatment market are pSivida Corp., XOMA Corporation, Alcon, Inc., Allergan, Inc., AbbVie Inc., Enzo Biochem Inc., OphthaliX Inc., Bausch & Lomb Incorporated, Regeneron Pharmaceuticals, Inc, and Santen Pharmaceutical Co., Ltd. These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.

Table Of Contents

Global Market Study on Uveitis Treatment: Asia to Witness fastest Growth by 2020
Chapter 1 Preface

1.1 Report Description

1.2 Research Methodology

1.3 Assumptions

Chapter 2 Market Synopsis

Chapter 3 Porter's Five Forces Analysis

3.1 Bargaining Power of Suppliers

3.2 Bargaining Power of Buyers

3.3 Threat of New Entrants

3.4 Threat of Substitutes

3.5 Intensity of Rivalry

Chapter 4 Industry Overview

4.1 Market Definition

4.2 Market drivers

4.2.1 Rising aging population

4.2.2 Increasing incidence of eye disorders

4.2.3 Growing government initiatives to reduce eye disorders

4.2.4 Increasing RandD investments in drug discovery and development

4.3 Impact Analysis of Market Drivers

4.4 Market restraints

4.4.1 Lack of awareness about eye disorders

4.4.2 Poor primary healthcare infrastructure and lack of health insurance in developing countries

4.5 Impact analysis of market restraints

4.6 Market Trends

4.6.1 Increasing usage of anti-TNF-alpha inhibitor therapy

4.6.2 Rising incidence of drug-induced uveitis

4.7 Market Opportunities

4.7.1 Use of electronic medical records

Chapter 5 Global Market Size and Forecast

Chapter 6 Market Size and Forecast by Type

6.1 Anterior uveitis

6.2 Posterior uveitis

6.3 Intermediate uveitis

6.4 Panuveitis

Chapter 7 Market Size and Forecast by Treatment

7.1 Anti-inflammatory medications

7.2 Antibiotic or antiviral medications

7.3 Immunosuppressive medications

Chapter 8 Market Size and Forecast by Geography

8.1 North America

8.1.1 Scenario in the U.S.

8.2 Europe

8.2.1 Scenario in Germany

8.2.2 Scenario in France

8.2.3 Scenario in the U.K

8.3 Asia

8.3.1 Scenario in Japan

8.3.2 Scenario in China

8.3.3 Scenario in India

Chapter 9 Pipeline Drugs for Uveitis Treatment

9.1 Drugs under development for Uveitis Treatment

Chapter 10 Competitive Scenario

10.1 Competitive Benchmarking

Chapter 11 Company Profiles

11.1 Regeneron Pharmaceuticals, Inc.

11.1.1 Company overview

11.1.2 Products and services

11.1.3 Financial performance

11.1.4 Key developments

11.2 pSivida Corp.

11.2.1 Company overview

11.2.2 Products and services

11.2.3 Financial performance

11.2.4 Key developments

11.3 XOMA Corporation

11.3.1 Company overview

11.3.2 Products and services

11.3.3 Financial performance

11.3.4 Key developments

11.4 Alcon, Inc.

11.4.1 Company overview

11.4.2 Products and services

11.4.3 Financial performance

11.4.4 Key developments

11.5 Allergan, Inc.

11.5.1 Company overview

11.5.2 Products and services

11.5.3 Financial performance

11.5.4 Key developments

11.6 AbbVie Inc.

11.6.1 Company overview

11.6.2 Products and segments

11.6.3 Financial performance

11.6.4 Key developments

11.7 Santen Pharmaceutical Co., Ltd.

11.7.1 Company overview

11.7.2 Products and segments

11.7.3 Financial performance

11.7.4 Key developments

11.8 Enzo Biochem Inc.

11.8.1 Company overview

11.8.2 Products and segments

11.8.3 Financial performance

11.8.4 Key developments

11.9 OphthaliX Inc.

11.9.1 Company overview

11.9.2 Products and segments

11.9.3 Financial performance

11.9.4 Key developments

11.10 Bausch and Lomb Incorporated

11.10.1 Company overview

11.10.2 Products and segments

11.10.3 Financial performance

11.10.4 Key developments

11.11 Artielle ImmunoTherapeutics, Inc.

11.11.1 Company overview

11.11.2 Products and segments

11.11.3 Financial performance

11.11.4 Key developments

11.12 Eyegate Pharmaceuticals, Inc.

11.12.1 Company overview

11.12.2 Products and segments

11.12.3 Financial performance

11.12.4 Key developments

List of Tables

TABLE 1 Market snapshot: Uveitis treatment market, 2014 and 2020

TABLE 2 Drivers for uveitis treatment market: Impact analysis

TABLE 3 Out-of-pocket expenditure of developing and developed countries in 2013

TABLE 4 Restraints for uveitis treatment market: Impact analysis

TABLE 5 Global uveitis treatment market size, by region, 2010 - 2013 (USD million)

TABLE 6 Global uveitis treatment market size, by region, 2014 - 2020 (USD million)

TABLE 7 Global uveitis treatment market size, by type, 2010 - 2013 (USD million)

TABLE 8 Global uveitis treatment market size, by type, 2014 - 2020 (USD million)

TABLE 9 Global uveitis treatment market size, by treatment, 2010 - 2013 (USD million)

TABLE 10 Global uveitis treatment market size, by treatment, 2014 - 2020 (USD million)

TABLE 11 Global anterior uveitis treatment market size, by region, 2010 - 2013 (USD million)

TABLE 12 Global anterior uveitis treatment market size, by region, 2014 - 2020 (USD million)

TABLE 13 Global posterior uveitis treatment market size, by region, 2010 - 2013 (USD million)

TABLE 14 Global posterior uveitis treatment market size, by region, 2014 - 2020 (USD million)

TABLE 15 Global intermediate uveitis treatment market size, by region, 2010 - 2013 (USD million)

TABLE 16 Global intermediate uveitis treatment market size, by region, 2014 - 2020 (USD million)

TABLE 17 Global panuveitis treatment market size, by region, 2010 - 2013 (USD million)

TABLE 18 Global panuveitis treatment market size, by region, 2014 - 2020 (USD million)

TABLE 19 Global anti-inflammatory medications market size, by region, 2010 - 2013 (USD million)

TABLE 20 Global anti-inflammatory medications market size, by region, 2014 - 2020 (USD million)

TABLE 21 Global antibiotic/antiviral medications market size, by region, 2010 - 2013 (USD million)

TABLE 22 Global antibiotic/antiviral medications market size, by region, 2014 - 2020 (USD million)

TABLE 23 Global immunosuppressive medications market size, by region, 2010 - 2013 (USD million)

TABLE 24 Global immunosuppressive medications market size, by region, 2014 - 2020 (USD million)

TABLE 25 The North American uveitis treatment market size, by country, 2010 - 2013 (USD million)

TABLE 26 The North American uveitis treatment market size, by country, 2014 - 2020 (USD million)

TABLE 27 The European uveitis treatment market size, by country, 2010 - 2013 (USD million)

TABLE 28 The European uveitis treatment market size, by country, 2014 - 2020 (USD million)

TABLE 29 The Asian uveitis treatment market size, by country, 2010 - 2013 (USD million)

TABLE 30 The Asian uveitis treatment market size, by country, 2014 - 2020 (USD million)

TABLE 31 Major pipeline drugs for uveitis treatment

TABLE 32 Product category of Regeneron Pharmaceuticals, Inc.

TABLE 33 Product category of pSivida Corp.

TABLE 34 Product category of XOMA Corporation

TABLE 35 Major product categories of Alcon, Inc.

TABLE 36 Major product categories of Allergan, Inc.

TABLE 37 Product segment of AbbVie Inc.

TABLE 38 Major product categories of Santen Pharaceutical Co., Ltd.

TABLE 39 Product segments of Enzo Biochem Inc.

TABLE 40 Product category of OphthaliX Inc.

TABLE 41 Major product categories of Bausch and Lomb Incorporated.

TABLE 42 Product category of Artielle ImmunoTherapeutics, Inc.

TABLE 43 Product category of Eyegate Pharmaceuticals, Inc.

List of Figures

FIG. 1 Uveitis treatment market: Porter's five forces analysis

FIG. 2 Major types of uveitis treatment

FIG. 3 Aging population in major countries, 2000 - 2050 (% share in total population)

FIG. 4 Global uveitis treatment market share, by region, by value, 2013

FIG. 5 Global uveitis treatment market share, by type, by value, 2013

FIG. 6 Global uveitis treatment market share, by treatment, by value, 2013

FIG. 7 Global anterior uveitis treatment market share, by region, by value, 2013

FIG. 8 Global posterior uveitis treatment market share, by region, by value, 2013

FIG. 9 Global intermediate uveitis treatment market share, by region, by value, 2013

FIG. 10 Global panuveitis treatment market share, by region, by value, 2013

FIG. 11 Global anti-inflammatory medications market share, by region, by value, 2013

FIG. 12 Global antibiotic or antiviral medications market share, by region, by value, 2013

FIG. 13 Global immunosuppressive medications market share, by region, by value, 2013

FIG. 14 The North American uveitis treatment market share, by country, by value, 2013

FIG. 15 The European uveitis treatment market share, by country, by value, 2013

FIG. 16 The Asian uveitis treatment market share, by country, by value, 2013

FIG. 17 Research and development expenditures of major players in the market

FIG. 18 Revenue and net income of Regeneron Pharmaceuticals, Inc., 2012 - 2014 (USD million)

FIG. 19 Total revenues and net income of pSivida Corp., 2012 - 2014 (USD million)

FIG. 20 Total revenue and net income of XOMA Corporation, 2011 - 2013 (USD million)

FIG. 21 Net sales and operating income of Alcon, Inc., 2011 - 2013 (USD million)

FIG. 22 Total revenues and operating income of Allergan, Inc., 2012 - 2014 (USD million)

FIG. 23 Net sales and net earnings of AbbVie Inc., 2012 - 2014 (USD million)

FIG. 24 Net sales and net income of Santen Pharmaceutical Co., Ltd., 2012 - 2014 (USD million)

FIG. 25 Revenues and net loss of Enzo Biochem Inc., 2012 - 2014 (USD million)

FIG. 26 Revenues and operating income of Valeant Pharmaceuticals International, Inc., 2012 - 2014 (USD million)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.